Launch of Sunway Medical School
The launch ceremony on 7 May 2025 at Sunway University was officiated by the Minister of Higher Education, Dato' Seri Diraja Dr Zambry Abd Kadir, and attended by Tan Sri Sir Jeffrey Cheah, Founder and Chairman of Sunway Group.
The medical school is set to equip the next generation of healthcare professionals with the knowledge, skills and compassion needed to address the evolving demands of global healthcare systems.
The launch of the Sir Jeffrey Cheah Sunway Medical School follows the establishment of the Jeffrey Cheah Biomedical Centre (JCBC) in Cambridge, reinforcing Cheah's commitment to advancing world-class education and biomedical research.
A highlight of the launch was the 'White Coat Ceremony' for the inaugural cohort of medical students, who also took the 'Hippocratic Oath', a symbolic and meaningful rite of passage marking their official induction into the medical profession.
The Doctor of Medicine (MD) programme at Sunway University offers a dynamic, future-ready medical curriculum supported by immersive clinical training at Sunway Medical Centre, a leading private hospital. Students gain hands-on experience in patient care, translating medical knowledge into real-world practical skills. The programme also fosters inter professional collaboration, preparing students to work effectively within diverse healthcare teams for a holistic understanding of patient care.
With a strong emphasis on clinical and translational research, sustainability and planetary health in medicine, digital healthcare technology including precision medicine and application of artificial intelligence in medicine, students are equipped to lead in tech-enabled healthcare environments. Beyond the hospital, the programme encourages community engagement through initiatives such as the Desa Mentari Project, nurturing socially responsible medical professionals dedicated to serving the community.
President of Sunway University, Professor Sibrandes Poppema said: 'The launch of the Sir Jeffrey Cheah Sunway Medical School represents a pivotal step forward in our mission to shape future-ready healthcare professionals. Our goal is to develop doctors and researchers who not only excel in medical knowledge and clinical skills but who are also equipped to lead with integrity, empathy, and innovation. This school will be a catalyst for transformative research, global collaboration, and sustainable healthcare solutions that benefit communities in Malaysia and beyond.'
With its future-ready medical curriculum, state-of-the-art clinical training, digital fluency, and global research collaborations, the Sir Jeffrey Cheah Sunway Medical School is set to become a leading institution in medical education across Asia. Its launch marks a new era of medical education innovation - one that supports the development of sustainable, technology-enhanced, and community-driven healthcare solutions for the future.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
5 hours ago
- The Star
Using AI play for early growth
Game changer uses technology to tackle development issues in children PETALING JAYA: As a child, Tokyo-born Shun Matsuzaka had boundless love for learning, but that passion rarely reflected in his grades, as he struggled to achieve good results. It wasn't until he was 19, during his foundation year at a university in the United Kingdom, that he was diagnosed with dyslexia. This changed not just his life but also shaped his ambition to help other children going through what he had to go through. Having moved to Malaysia in 2017, Matsuzaka, along with his partner Masaki Ishibashi, founded TOY8 in 2018, a social impact venture designed to unlock every child's potential through play and data. Together, they planned to establish an AI-powered playground in 2020 in a 45,000sq ft (4,180sq m) space at a mall in Kuala Lumpur. Filled with motion sensors and cameras, the playground would allow them to observe children's play and extract insights into their cognitive and motor strengths, which would then be explained to the parents if any issues were found. Sadly, the plan was derailed even before it could take off following the Covid-19 pandemic. TOY8 co-founder Matsuzaka. Defeated but not beaten, Matsuzaka was then inspired by a letter he received from the Tokyo city office – an invitation for his daughter to attend a mandatory three-year-old developmental screening. 'It was then I realised that while this was standard practice in Japan, Malaysia had no equivalent system for those aged between three and six – a gap in the most crucial window of brain development. 'Most parents had no structured way to know whether their child's development was on track or not and this gap, between the need for early detection and the absence of reliable access, became our new focus,' he said. Matsuzaka and his team then developed the first AI-powered, gamified screening and intervention system in Malaysia in 2022 in collaboration with Sunway University, Universiti Malaya, the Health Ministry Clinical Research Centre and a former Nintendo game director. The system utilised smartphone-based games to screen five core domains of development – language, cognition, fine and gross motor skills and social-emotional abilities. 'These games are intentionally designed to be exciting, intuitive and culturally relevant, enabling teachers in preschools and kindergartens to conduct reliable developmental checks during classroom time without requiring clinical expertise. 'If a child is flagged for mild or moderate developmental support needs, they can be supported through the TOY8 intervention programme, which offers over 3,000 plus fun game activities personalised to the child's profile. 'These interventions can then be delivered at school or home with the guidance of trained educators or caregivers,' Matsuzaka said. Matsuzaka also said TOY8's system empowers teachers with technology, not only to screen and support children but also to actively participate in the reduction of developmental inequality. 'Instead of relying solely on overburdened specialists, we shifted part of the responsibility to well-equipped preschool classrooms, ensuring that more children are identified early and supported effectively during the brain's most critical years of development.' Since its inception, TOY8 has screened over 15,000 children across Malaysia and other Asean countries with Sarawak becoming one of the first Malaysian states to adopt the model at scale in 2023. By integrating digital screening into its public preschools, the state now stands as a beacon of inclusive early education, not just in Malaysia but for the entire Asean region. 'By the end of the year, our programme in Sarawak will expand to screen 600 children, supported by a growing network of trained educators and interventionists. 'We are now hoping to present the Sarawak model as a regional policy proposal at the 2025 Asean Business Summit under the Inclusive Education 2.0 framework, as well as expand our reach to other Asean countries,' he added. Meanwhile, the Star Golden Hearts Award (SGHA) returns for the 11th edition to honour everyday Malaysians whose compassion and selflessness have made a lasting impact on others. With McDonald's Malaysia as the new strategic partner, SGHA is poised to broaden its reach and deepen its impact nationwide. This year also marks the debut of the McDonald's Caring Hearts Award – a special recognition honouring individuals or grassroots groups whose heartfelt acts of kindness have uplifted lives in profound and lasting ways. Since its inception in 2015, SGHA has honoured over 100 individuals and organisations whose efforts have inspired action, transformed lives and strengthened communities nationwide.
The Star
3 days ago
- The Star
Game-changing treatment for advanced prostate cancer
Prostate cancer is the third most common cancer among Malaysian men, with cases rising steadily since 2012. While it trails behind colorectal and lung cancer, it is still a significant concern. What's more worrying is that many cases are detected late. Early-stage prostate cancer is highly treatable, but late-stage cases are far more difficult to manage. What is prostate cancer? The disease begins when cells in the prostate – a small, walnut-sized gland below the bladder – start to grow uncontrollably. In its early stages, prostate cancer often causes no symptoms. But as the tumour grows, it can press against the urethra – the tube that carries urine – leading to changes in urination. Left untreated, the cancer can spread to nearby tissues, lymph nodes, or even the bones, making it more difficult to treat and manage. Yet, many men overlook the early signs. However, symptoms such as difficulty urinating, weak flow, or frequent trips to the bathroom at night may be early warning signs of prostate cancer. Sunway University consultant urologist and urologic oncologist Professor Dr Tan Guan Hee explains that these symptoms often go unnoticed or are mistaken for benign prostate conditions such as benign prostatic hyperplasia. 'Many men assume it's just part of getting older and delay seeing a doctor,' he says. 'Unfortunately, this means prostate cancer is often diagnosed at a later stage, when it's more difficult to treat.' As Malaysia's population continues to age, the number of prostate-related issues is expected to rise in tandem. Despite this, there is a general lack of awareness of the problem, minimal symptoms in early stages, and a cultural reluctance to seek help for intimate health issues. When prostate cancer is detected early, treatment options such as surgery or radiotherapy are often effective and potentially curative. However, late-stage prostate cancer, which may have already spread to bones or lymph nodes (metastasised), requires more advanced interventions. This is where radioligand therapy (RLT) offers new hope. Overcoming stigma One significant and often overlooked challenge in managing prostate cancer is cultural reluctance. Many patients delay seeking care due to embarrassment or denial, particularly Asian men, who may be more reserved about discussing health issues. Doctors often find that families bring in patients who have ignored symptoms for years. Prof Tan says: 'Addressing this cultural barrier requires greater public awareness, normalising conversations around men's health, and encouraging routine screening and early intervention.' Beyond individual awareness, family involvement plays a critical role in detecting early symptoms of prostate cancer and preventing critical outcomes. 'If children notice their father is frequently going to the toilet, they might realise something is amiss and encourage him to seek medical help,' he suggests. Treatment for prostate cancer depends on what stage the tumour is at. — Photos: Canva Precision treatment According to consultant clinical oncologist Dr Nik Muhd Aslan Abdullah, treatment for prostate cancer has come a long way since the 1990s. While surgery, radiotherapy and hormonal therapy remain standard options, recent advances in precision medicine have led to more targeted, effective treatments. Choosing the most appropriate treatment depends on several factors, including: > The stage of the cancer > The patient's age > Personal preferences > Underlying health conditions that may make certain treatments, such as surgery, unsuitable. 'In the past, our precision treatment options were quite limited. 'But today, we are guided by clearer staging and more accurate tools,' he says. Dr Nik outlines the four key stages that influence treatment strategy: > Stage 1: The tumour is confined to the prostate and involves no more than half of the gland. > Stage 2: The tumour remains within the prostate but is more advanced. > Stage 3: The tumour has grown beyond the prostate and may have reached nearby structures such as the seminal vesicles, rectum or bladder. > Stage 4: The cancer has spread to the lymph nodes or distant parts of the body, such as the bones. 'To determine the stage, we typically rely on three approaches: physical examination, blood tests, particularly for prostate-specific antigen (PSA), and imaging. 'Conventional imaging includes computed tomography (CT) scans, magnetic resonance imaging (MRI), and bone scans,' he explains. However, these methods have their limitations. Dr Nik adds: 'They may miss early tumours or small areas of spread, and while blood tests are helpful, they cannot show the precise location of the cancer.' Sharper detection with PSMA PET-CT A key development is PSMA PET-CT imaging – a powerful diagnostic tool that combines positron emission tomography (PET) with CT to detect prostate-specific membrane antigen (PSMA), a protein found on most prostate cancer cells. 'About 80% of prostate cancer cells have a protein called PSMA on their surface,' explains Sunway University consultant nuclear medicine physician Associate Prof Dr Tan Teik Hin. 'We use this to both detect and treat cancer. The approach is simple: we treat what we see, and we see what we treat.' PSMA PET-CT works like a GPS for cancer cells. The CT maps the body's structure, while the PET scan lights up areas where PSMA-positive cancer cells are present. It can detect tumours as small as 0.3cm, far smaller than what conventional scans typically reveal. In an April 2020 ProPSMA study published in The Lancet , researchers found that this method was 27% more accurate than traditional imaging, often leading to significant changes in treatment planning. What is radioligand therapy or RLT? Once PSMA-positive cancer cells are identified, patients may be eligible for RLT. This treatment uses a radioactive compound that binds specifically to PSMA on cancer cells, delivering a precise dose of radiation directly to the tumour while sparing surrounding healthy tissue. Assoc Prof Teik Hin says: 'It's like sending a guided missile to destroy only the cancer cells. 'RLT is not entirely new. A similar concept – using radioactive iodine to treat thyroid cancer – has been in use for over 80 years. 'What's new is applying the same principle to prostate cancer using more advanced, highly specific radiotracers.' After treatment, a follow-up scan (SPECT-CT, a hybrid imaging technique that combines Single Photon Emission Computed Tomography and CT) is conducted to confirm that the radioligand successfully reached and treated the target. From left: Assoc Prof Teik Hin, Prof Tan and Dr Nik were the three medical professionals who led the roundtable discussion on RLT. — Handout Fewer side effects One of the greatest advantages of RLT is its specificity. Because the therapy targets only cancerous cells, it causes fewer side effects compared to systemic treatments like chemotherapy or hormonal therapy. Most patients tolerate it well, with mild side effects such as dry mouth, fatigue or nausea. More importantly, studies show that RLT can help delay disease progression, reduce symptoms like pain, and improve quality of life, especially for men with advanced or castration-resistant prostate cancer. While RLT is currently used mainly for patients with stage 4 prostate cancer who no longer respond to other treatments, ongoing clinical trials are exploring its use at earlier stages. PSMA PET-CT is also being studied for its ability to guide biopsies and detect cancer even before a formal diagnosis is made. 'Compared to systemic hormone therapy, which affects the entire body and can cause fatigue and mood changes, RLT offers a more targeted approach with fewer disruptions to daily life. 'We see a marked improvement in quality of life, and patients report less pain, more energy, and better sleep after the therapy,' says Assoc Prof Teik Hin. The treatment is available at government facilities such as the National Cancer Institute (IKN) in Putrajaya and Hospital Kuala Lumpur, as well as at several private hospitals. The cost of RLT varies depending on the hospital, the number of treatment cycles, and individual response to the treatment. As there is no fixed price, patients are encouraged to consult their medical team to discuss affordability and explore available financial support options. The three experts were discussing 'Size Matters in Prostate Cancer: Experts Highlight Advances to Close Critical Gaps in Care,' in a media roundtable held recently at a private hospital in Petaling Jaya, Selangor.
Malay Mail
23-07-2025
- Malay Mail
Minister clarifies halal status of Hospital Canselor Tuanku Muhriz caterer amid audit report concerns
KUALA LUMPUR, July 23 — Higher Education Minister Datuk Seri Zambry Abd Kadir today clarified that the delay in halal certification for the food service provider awarded the patient meal contract at Hospital Canselor Tuanku Muhriz (HCTM) was due to technical issues in the application process, not non-compliance with halal standards. He said the matter should not alarm the public, as it does not suggest the company involved is operating outside halal requirements. 'The issue is not that the company doesn't practise halal procedures, but rather a technical delay in obtaining the certificate. 'The halal certification process in Malaysia applies not to the company as a whole, but to the specific premises,' he said during the debate on the Auditor-General's Report in Parliament today. Zambry explained that once a company is awarded a tender, it is typically given six months to apply for halal certification. However, in this case, the process took more than a year due to administrative setbacks, including delays in appointing a Person in Charge (PIC), which is required for the certification process. 'The company was awarded the tender in 2024, but the PIC was only appointed on April 14, 2025. Without the PIC, the company could not even begin the application process. 'Only after the PIC is in place can the company begin uploading details into the halal system, undergo audits, and proceed with inspections,' he said. This lengthy, sequential process, Zambry said, led to delays that exceeded the stipulated six-month period. He also noted that while the specific premises used for HCTM had yet to be certified, other premises under the same company already held valid halal certification. He added that all food suppliers working with the company were halal-certified. 'This shows that the company does observe halal standards. The issue lies with procedural inefficiencies that we need to correct moving forward,' he said. On Monday, the Auditor-General's Report (LKAN) 2/2025 revealed that HCTM had awarded a three-year catering contract worth RM25.64 million to a company that did not yet possess halal certification from the Department of Islamic Development Malaysia (Jakim). According to the report, the company was granted the tender to supply patient meals at HCTM from February 2024 to February 2027. The report also noted that the objective of the tender was to provide halal meals to patients, in line with the hospital's Main Kitchen, which is certified halal by Jakim.
